DRL launches of Aripiprazole tablets in the US

A therapeutic equivalent generic version of Abilify (aripiprazole) is available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg tablets

Dr Reddy’s Laboratories (DRL) has launched Aripiprazole tablets, USP, in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, a therapeutic equivalent generic version of Abilify (aripiprazole) tablets in the US market approved by the US Food & Drug Administration (USFDA).

DRL’s Aripiprazole tablets 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg are available in bottle count sizes of 30.

EP News Bureau